This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Naline, E Articles by Advenier, C Search for Related Content PubMed PubMed Citation Articles by Naline, E Articles by Advenier, C

Original Articles

Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus

The objective of this study was to evaluate the potency and efficacy (intrinsic activity) of formoterol and salmeterol and their duration of action in comparison with other beta-adrenoceptor agonists in isolated human bronchi. Human bronchi were obtained at thoracotomy from patients with lung cancer. Potency (-log of the concentration of drug inducing 50% of maximal relaxation (-log EC50)) and efficacy (maximal effect (Emax), % of response to theophylline 3 x 10(-3) mol.l-1) were determined by analysis of cumulative isometric concentration-response curves to beta 2-adrenoceptor agonists in bronchial rings at resting tone or contracted maximally with acetylcholine 10(-3) mol.l-1 to induce functional antagonism. The onset and duration of action of beta-adrenoceptor agonists were measured by assessing the relaxant activity of drugs on the basal tone of isolated bronchi. In terms of potency, the rank order of the substances studied was formoterol > fenoterol > or = salmeterol > or = isoprenaline > or = salbutamol > or = adrenaline > or = terbutaline. Formoterol was 150-200 times more potent than isoprenaline. On preparations contracted with acetylcholine 10(-3) mol.l-1 the intrinsic activity (IA) of salbutamol, terbutaline and salmeterol compared with that of isoprenaline ranged 0.62-0.66. Intrinsic activity was higher with formoterol (0.84) and fenoterol (0.75). The onset of action of formoterol (2.14 +/- 0.55 min, n = 11) was not significantly different from that of salbutamol (1.90 +/- 0.24 min, n = 8) but shorter than that of salmeterol (6.40 +/- 1.40 min, n = 10).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				R. G. Sturton, A. Trifilieff, A. G. Nicholson, and P. J. Barnes Pharmacological Characterization of Indacaterol, a Novel Once Daily Inhaled 2 Adrenoceptor Agonist, on Small Airways in Human and Rat Precision-Cut Lung Slices J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 270 - 275. [Abstract] [Full Text] [PDF]

				E. Naline, A. Trifilieff, R. A. Fairhurst, C. Advenier, and M. Molimard Effect of indacaterol, a novel long-acting {beta}2-agonist, on isolated human bronchi Eur. Respir. J., March 1, 2007; 29(3): 575 - 581. [Abstract] [Full Text] [PDF]

				B. Adelsberg Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief Evid. Based Med., October 1, 2006; 11(5): 138 - 138. [Full Text] [PDF]

				P. M. O'Byrne and E. Adelroth {beta}2 Deja Vu Chest, January 1, 2006; 129(1): 3 - 5. [Full Text] [PDF]

				V. Lagente, E. Naline, I. Guenon, M. Corbel, E. Boichot, J.-L. Burgaud, P. Del Soldato, and C. Advenier A Nitric Oxide-Releasing Salbutamol Elicits Potent Relaxant and Anti-Inflammatory Activities J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 367 - 375. [Abstract] [Full Text] [PDF]

				C. Faisy, E. Naline, J.-L. Diehl, X. Emonds-Alt, T. Chinet, and C. Advenier In vitro sensitization of human bronchus by beta 2-adrenergic agonists Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L1033 - L1042. [Abstract] [Full Text] [PDF]

				J. A. Nightingale, D. F. Rogers, and P. J. Barnes Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma* Chest, May 1, 2002; 121(5): 1401 - 1406. [Abstract] [Full Text] [PDF]

				J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]

				T. Katsunuma, A. F. Roffel, C. R. S. Elzinga, J. Zaagsma, P. J. Barnes, and J. C. W. Mak beta 2-Adrenoceptor Agonist-Induced Upregulation of Tachykinin NK2 Receptor Expression and Function in Airway Smooth Muscle Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 409 - 417. [Abstract] [Full Text]

				M. PALMQVIST, T. IBSEN, A. MELLEN, and J. LOTVALL Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 244 - 249. [Abstract] [Full Text]

				A. Teschemacher and H. Lemoine Kinetic Analysis of Drug-Receptor Interactions of Long-Acting beta 2 Sympathomimetics in Isolated Receptor Membranes: Evidence against Prolonged Effects of Salmeterol and Formoterol on Receptor-Coupled Adenylyl Cyclase J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1084 - 1092. [Abstract] [Full Text]